Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option?

References

• Pompili M, Lester D, Innamorati M, Tatarelli R, Girardi P. Assessment and treatment of suicide risk in schizophrenia. Expert Rev. Neurother.8(1), 51–74 (2008).
   PubMedGoogle Scholar
• American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia. American Psychiatric Association, DC, USA (2004).
   Google Scholar
• Green MF. Stimulating the development of drug treatments to improve cognition in schizophrenia. Annu. Rev. Clin. Psychol.3, 159–180 (2007).
   PubMedGoogle Scholar
• Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry153(3), 321–330 (1996).
   PubMed Web of Science ®Google Scholar
• Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology12(3), 426–445 (1998).
   PubMed Web of Science ®Google Scholar
• Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry158(2), 176–184 (2001).
   PubMed Web of Science ®Google Scholar
• Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr. Bull.25(2), 201–222 (1999).
   PubMed Web of Science ®Google Scholar
• Keefe RS, Seidman LJ, Christensen BK et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am. J. Psychiatry161(6), 985–995 (2004).
   PubMed Web of Science ®Google Scholar
• Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull.25(2), 233–255 (1999).
   PubMed Web of Science ®Google Scholar
• Green MF, Marder SR, Glynn SM et al. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol. Psychiatry51(12), 972–978 (2002).
   PubMed Web of Science ®Google Scholar
• Keefe RS, Bilder RM, Davis SM et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry64(6), 633–647 (2007).
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J. Clin. Psychopharmacol.24(5 Suppl. 1), S7–S14 (2004).
   PubMedGoogle Scholar
• Nagamoto HT. Antipsychotic medications. In: Psychiatric Secrets. Jacobson JL, Jacobson AM (Eds). Hanley and Belfus Inc., PA, USA, 253–259 (2001).
   Google Scholar
• Kane JM. Schizophrenia. N. Engl. J. Med.334(1), 34–41 (1996).
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr. Res.66(1), 51–57 (2004).
   PubMed Web of Science ®Google Scholar
• Fakhoury WK, Wright D, Wallace M. Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline. Int. Clin. Psychopharmacol.16(3), 153–162 (2001).
   PubMed Web of Science ®Google Scholar
• Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ321(7273), 1371–1376 (2000).
   PubMed Web of Science ®Google Scholar
• Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am. J. Psychiatry160(7), 1209–1222 (2003).
   PubMed Web of Science ®Google Scholar
• Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry161(3), 414–425 (2004).
   PubMed Web of Science ®Google Scholar
• Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology28(Suppl. 1), 9–26 (2003).
   PubMed Web of Science ®Google Scholar
• Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry60(6), 553–564 (2003).
   PubMed Web of Science ®Google Scholar
• Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br. J. Psychiatry177, 212–217 (2000).
   PubMed Web of Science ®Google Scholar
• Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care27(2), 596–601 (2004).
   PubMed Web of Science ®Google Scholar
• Taylor D. Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs17(6), 423–430 (2003).
   PubMed Web of Science ®Google Scholar
• Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J. Clin. Psychiatry61(10), 742–749 (2000).
   PubMed Web of Science ®Google Scholar
• Henderson DC, Cagliero E, Gray C et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am. J. Psychiatry157(6), 975–981 (2000).
   PubMed Web of Science ®Google Scholar
• Casey DE, Haupt DW, Newcomer JW et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J. Clin. Psychiatry65(Suppl. 7), 4–18; quiz 19–20 (2004).
   PubMed Web of Science ®Google Scholar
• Fontaine KR, Heo M, Harrigan EP et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res.101(3), 277–288 (2001).
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Haupt DW, Fucetola R et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry59(4), 337–345 (2002).
   PubMed Web of Science ®Google Scholar
• Tandon R, Belmaker RH, Gattaz WF et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr. Res.100(1–3), 20–38 (2008).
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet373(9657), 31–41 (2009).
   PubMed Web of Science ®Google Scholar
• Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry14(4), 429–447 (2009).
   PubMed Web of Science ®Google Scholar
• Boter H, Peuskens J, Libiger J et al. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr. Res.115(2–3), 97–103 (2009).
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med.353(12), 1209–1223 (2005).
   PubMed Web of Science ®Google Scholar
• Perkins DO. Predictors of noncompliance in patients with schizophrenia. J. Clin. Psychiatry63(12), 1121–1128 (2002).
   PubMed Web of Science ®Google Scholar
• Tacchi MJ, Scott J. Improving Adherence in Schizophrenia and Bipolar Disorders. Wiley, Chichester, UK (2005).
   Google Scholar
• Tatarelli R. Drugs and human interactions. Ann. Ist Super Sanita28(2), 197–202 (1992).
   PubMedGoogle Scholar
• Noble LM. Doctor-patient communication and adherence to treatment. In: Adherence to Treatment in Medical Conditions. Myer LB, Midence K (Eds). Wiley, London, UK, 51–82 (1998).
   Google Scholar
• Valenstein M, Blow FC, Copeland LA et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr. Bull.30(2), 255–264 (2004).
   PubMed Web of Science ®Google Scholar
• Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr. Serv.49(2), 196–201 (1998).
   PubMed Web of Science ®Google Scholar
• Davis JM, Kane JM, Marder SR et al. Dose response of prophylactic antipsychotics. J. Clin. Psychiatry54(Suppl.), 24–30 (1993).
   PubMed Web of Science ®Google Scholar
• Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr. Bull.23(4), 637–651 (1997).
   PubMed Web of Science ®Google Scholar
• Robinson D, Woerner MG, Alvir JM et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry56(3), 241–247 (1999).
   PubMed Web of Science ®Google Scholar
• Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr. Serv.54(5), 719–723 (2003).
   PubMed Web of Science ®Google Scholar
• Gilmer TP, Dolder CR, Lacro JP et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am. J. Psychiatry161(4), 692–699 (2004).
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J. Clin. Psychiatry68(Suppl. 4), 8–13 (2007).
   PubMed Web of Science ®Google Scholar
• Hennekens CH. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. J. Clin. Psychiatry68(Suppl. 4), 4–7 (2007).
   PubMed Web of Science ®Google Scholar
• Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch. Gen. Psychiatry64(10), 1123–1131 (2007).
   PubMed Web of Science ®Google Scholar
• Gough SC, O’Donovan MC. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? J. Psychopharmacol.19(6 Suppl.), 47–55 (2005).
   PubMedGoogle Scholar
• Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet. Med.24(5), 481–485 (2007).
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs19(Suppl. 1), 1–93 (2005).
   PubMed Web of Science ®Google Scholar
• Sengupta S, Parrilla-Escobar MA, Klink R et al. Are metabolic indices different between drug-naive first-episode psychosis patients and healthy controls? Schizophr. Res.102(1–3), 329–336 (2008).
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Metabolic risk during antipsychotic treatment. Clin. Ther.26(12), 1936–1946 (2004).
   PubMed Web of Science ®Google Scholar
• Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can. J. Psychiatry51(8), 492–501 (2006).
   PubMed Web of Science ®Google Scholar
• De Hert M, Schreurs V, Vancampfort D, Van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry8(1), 15–22 (2009).
   PubMed Web of Science ®Google Scholar
• Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr. Res.45(1–2), 21–28 (2000).
   PubMed Web of Science ®Google Scholar
• Johnsen E. Review: metabolic side effects of second-generation antipsychotics. Evid. Based Ment. Health14(2), 47 (2011).
   PubMedGoogle Scholar
• De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur. Psychiatry26(3), 144–158 (2011).
   PubMed Web of Science ®Google Scholar
• DeBattista C, DeBattista K. Safety considerations of the use of second generation antipsychotics in the treatment of major depression: extrapyramidal and metabolic side effects. Curr. Drug Saf.5(3), 263–266 (2010).
   PubMedGoogle Scholar
• Shirzadi AA, Ghaemi SN. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv. Rev. Psychiatry14(3), 152–164 (2006).
   PubMed Web of Science ®Google Scholar
• Rummel-Kluge C, Komossa K, Schwarz S et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr. Res.123(2–3), 225–233 (2010).
   PubMed Web of Science ®Google Scholar
• Hasnain M, Vieweg WV, Fredrickson SK, Beatty-Brooks M, Fernandez A, Pandurangi AK. Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications. Prim. Care Diabetes3(1), 5–15 (2009).
   PubMedGoogle Scholar
• Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr. Res.70(1), 1–17 (2004).
   PubMed Web of Science ®Google Scholar
• Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr. Scand.119(3), 171–179 (2009).
   PubMed Web of Science ®Google Scholar
• Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr. Opin. Endocrinol. Diabetes Obes.17(5), 460–466 (2010).
   PubMed Web of Science ®Google Scholar
• Elman I, Borsook D, Lukas SE. Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology31(10), 2091–2120 (2006).
   PubMedGoogle Scholar
• Rondanelli M, Sarra S, Antoniello N et al. No effect of atypical antipsychotic drugs on weight gain and risk of developing Type II diabetes or lipid abnormalities among nursing home elderly patients with Alzheimer’s disease. Minerva Med.97(2), 147–151 (2006).
   PubMedGoogle Scholar
• Kinon BJ, Volavka J, Stauffer V et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J. Clin. Psychopharmacol.28(4), 392–400 (2008).
   PubMed Web of Science ®Google Scholar
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation106(25), 3143–3421 (2002).
   PubMed Web of Science ®Google Scholar
• Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA288(21), 2709–2716 (2002).
   PubMed Web of Science ®Google Scholar
• Haupt DW, Newcomer JW. Abnormalities in glucose regulation associated with mental illness and treatment. J. Psychosom. Res.53(4), 925–933 (2002).
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Meyer JM, Goff DC et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res.80(1), 19–32 (2005).
   PubMed Web of Science ®Google Scholar
• Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr. Scand.119(1), 4–14 (2009).
   PubMed Web of Science ®Google Scholar
• De Hert M, Schreurs V, Sweers K et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr. Res.101(1–3), 295–303 (2008).
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ. Atypical antipsychotic drugs and the risk of sudden cardiac death. N. Engl. J. Med.360(20), 2136–2137; author reply 2137–2138 (2009).
   PubMedGoogle Scholar
• Correll CU, Harris JL, Pantaleon Moya RA, Frederickson AM, Kane JM, Manu P. Low-density lipoprotein cholesterol in patients treated with atypical antipsychotics: missed targets and lost opportunities. Schizophr. Res.92(1–3), 103–107 (2007).
   PubMed Web of Science ®Google Scholar
• Barnett AH, Millar HL, Loze JY, L’Italien GJ, van Baardewijk M, Knapp M. UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). Eur. Arch. Psychiatry Clin. Neurosci.259(4), 239–247 (2009).
   PubMedGoogle Scholar
• Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N. Engl. J. Med.360(3), 225–235 (2009).
   PubMed Web of Science ®Google Scholar
• Correll CU, Frederickson AM, Figen V et al. The QTc interval and its dispersion in patients receiving two atypical antipsychotics. Eur. Arch. Psychiatry Clin. Neurosci.259(1), 23–27 (2009).
   PubMed Web of Science ®Google Scholar
• Harrigan EP, Miceli JJ, Anziano R et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J. Clin. Psychopharmacol.24(1), 62–69 (2004).
   PubMed Web of Science ®Google Scholar
• Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am. J. Psychiatry158(11), 1774–1782 (2001).
   PubMed Web of Science ®Google Scholar
• Fenton M, Rathbone J, Reilly J, Sultana A. Thioridazine for schizophrenia. Cochrane Database Syst. Rev. (3), CD001944 (2007).
   Google Scholar
• Elbe D, Carandang CG. Focus on ziprasidone: a review of its use in child and adolescent psychiatry. J. Can. Acad. Child Adolesc. Psychiatry17(4), 220–229 (2008).
   PubMedGoogle Scholar
• Jolly K, Gammage MD, Cheng KK, Bradburn P, Banting MV, Langman MJ. Sudden death in patients receiving drugs tending to prolong the QT interval. Br. J. Clin. Pharmacol.68(5), 743–751 (2009).
   PubMed Web of Science ®Google Scholar
• Mackin P. Cardiac side effects of psychiatric drugs. Hum. Psychopharmacol.23(Suppl. 1), 3–14 (2008).
   PubMed Web of Science ®Google Scholar
• Ravin DS, Levenson JW. Fatal cardiac event following initiation of risperidone therapy. Ann. Pharmacother.31(7–8), 867–870 (1997).
   PubMed Web of Science ®Google Scholar
• Cysneiros RM, Terra VC, Machado HR et al. May the best friend be an enemy if not recognized early: possible role of omega-3 against cardiovascular abnormalities due to antipsychotics in the treatment of autism. Arq. Neuropsiquiatr.67(3B), 922–926 (2009).
   PubMedGoogle Scholar
• Tiihonen J, Lonnqvist J, Wahlbeck K et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet374(9690), 620–627 (2009).
   PubMed Web of Science ®Google Scholar
• Taylor D. Typical and atypical antipsychotics increase risk of sudden cardiac death. Evid. Based Ment. Health12(3), 92 (2009).
   PubMedGoogle Scholar
• Herrmann N, Lanctot KL. Atypical antipsychotics for neuropsychiatric symptoms of dementia: malignant or maligned? Drug Saf.29(10), 833–843 (2006).
   PubMedGoogle Scholar
• Jerrell JM, McIntyre RS. Cerebro- and cardiovascular conditions in adults with schizophrenia treated with antipsychotic medications. Hum. Psychopharmacol.22(6), 361–364 (2007).
   PubMedGoogle Scholar
• Roh S, Ahn DH, Nam JH, Yang BH, Lee BH, Kim YS. Cardiomyopathy associated with clozapine. Exp. Clin. Psychopharmacol.14(1), 94–98 (2006).
   PubMed Web of Science ®Google Scholar
• Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs21(11), 911–936 (2007).
   PubMed Web of Science ®Google Scholar
• Dodd ML, Dolenc TJ, Karpyak VM, Rasmussen KG. QTc dispersion in patients referred for electroconvulsive therapy. J. Ect.24(2), 131–133 (2008).
   PubMedGoogle Scholar
• Schneider RA, Lizer MH. Apparent seizure and atrial fibrillation associated with paliperidone. Am. J. Health Syst. Pharm.65(22), 2122–2125 (2008).
   PubMed Web of Science ®Google Scholar
• Wang JF, Min JY, Hampton TG et al. Clozapine-induced myocarditis: role of catecholamines in a murine model. Eur. J. Pharmacol.592(1–3), 123–127 (2008).
   PubMed Web of Science ®Google Scholar
• Ariyarajah V, Shaikh N, Garber PJ, Kirkpatrick I, McGregor R, Jassal DS. Cardiovascular magnetic resonance in mild to moderate clozapine-induced myocarditis: is there a role in the absence of electrocardiographic and echocardiographic abnormalities? J. Magn. Reson. Imaging31(6), 1473–1476 (2010).
   PubMed Web of Science ®Google Scholar
• Nahshoni E, Strasberg B, Imbar S et al. Late potentials in the signal-averaged electrocardiogram in schizophrenia patients maintained on antipsychotic agents: a preliminary naturalistic study. Eur. Neuropsychopharmacol.20(3), 146–152 (2010).
   PubMedGoogle Scholar
• Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev.13(2), 137–177 (2007).
   PubMedGoogle Scholar
• Nakagawa S, Pedersen L, Olsen ML, Mortensen PB, Sorensen HT, Johnsen SP. Antipsychotics and risk of first-time hospitalization for myocardial infarction: a population-based case-control study. J. Intern. Med.260(5), 451–458 (2006).
   PubMed Web of Science ®Google Scholar
• Riedel M, Eich FX, Moller HJ. A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients. Eur. Psychiatry24(3), 149–153 (2009).
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Uchida H, Suzuki T, Watanabe K, Kashima H. Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: one-year follow-up study. Psychiatry Clin. Neurosci.64(1), 104–106 (2010).
   PubMed Web of Science ®Google Scholar
• Razminia M, Salem Y, Devaki S, Shah N, Khosla S. Clozapine induced myopericarditis: early recognition improves clinical outcome. Am. J. Ther.13(3), 274–276 (2006).
   PubMedGoogle Scholar
• Thieda P, Beard S, Richter A, Kane J. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr. Serv.54(4), 508–516 (2003).
   PubMed Web of Science ®Google Scholar
• Rittmannsberger H, Pachinger T, Keppelmuller P, Wancata J. Medication adherence among psychotic patients before admission to inpatient treatment. Psychiatr. Serv.55(2), 174–179 (2004).
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am. J. Psychiatry168, 603–609 (2011).
   PubMed Web of Science ®Google Scholar
• Palmer CS, Brunner E, Ruiz-Flores LG, Paez-Agraz F, Revicki DA. A cost–effectiveness clinical decision analysis model for treatment of schizophrenia. Arch. Med. Res.33(6), 572–580 (2002).
   PubMed Web of Science ®Google Scholar
• Hamilton SH, Revicki DA, Genduso LA, Beasley CM Jr. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology18(1), 41–49 (1998).
   PubMed Web of Science ®Google Scholar
• Davies A, Langley PC, Keks NA, Catts SV, Lambert T, Schweitzer I. Risperidone versus haloperidol: II. Cost–effectiveness. Clin. Ther.20(1), 196–213 (1998).
   PubMed Web of Science ®Google Scholar
• Palmer CS, Revicki DA, Genduso LA, Hamilton SH, Brown RE. A cost–effectiveness clinical decision analysis model for schizophrenia. Am. J. Manag. Care4(3), 345–355 (1998).
   PubMed Web of Science ®Google Scholar
• Bounthavong M, Okamoto MP. Decision analysis model evaluating the cost–effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia. J. Eval. Clin. Pract.13(3), 453–460 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenheck RA, Leslie DL, Sindelar J et al. Cost–effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am. J. Psychiatry163(12), 2080–2089 (2006).
   PubMed Web of Science ®Google Scholar
• Polsky D, Doshi JA, Bauer MS, Glick HA. Clinical trial-based cost–effectiveness analyses of antipsychotic use. Am. J. Psychiatry163(12), 2047–2056 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenheck RA, Perlick D, Bingham S et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA290(20), 2693–2702 (2003).
   PubMed Web of Science ®Google Scholar
• Gibson PJ, Damler R, Jackson EA, Wilder T, Ramsey JL. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a Medicaid population. Value Health7(1), 22–35 (2004).
   PubMed Web of Science ®Google Scholar
• Hargreaves WA, Gibson PJ. Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review. CNS Drugs19(5), 393–410 (2005).
   PubMedGoogle Scholar
• Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R. Cost–effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health9(2), 77–89 (2006).
   PubMed Web of Science ®Google Scholar
• Vera-Llonch M, Delea TE, Richardson E, Rupnow M, Grogg A, Oster G. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model. Value Health7(5), 569–584 (2004).
   PubMed Web of Science ®Google Scholar
• Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, ‘just the facts’ 4. Clinical features and conceptualization. Schizophr. Res.110(1–3), 1–23 (2009).
   PubMed Web of Science ®Google Scholar
• Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, ‘just the facts’ 5. Treatment and prevention. Past, present, and future. Schizophr. Res.122(1–3), 1–23 (2010).
   PubMed Web of Science ®Google Scholar
• Kane JM, Correll CU. Pharmacologic treatment of schizophrenia. Dialogues Clin. Neurosci.12(3), 345–357 (2010).
   PubMedGoogle Scholar
• Patterson TL, Leeuwenkamp OR. Adjunctive psychosocial therapies for the treatment of schizophrenia. Schizophr. Res.100(1–3), 108–119 (2008).
   PubMed Web of Science ®Google Scholar
• Costall B, Domeney AM, Kelly ME, Naylor RJ, Tomkins DM. Actions of ORG 5222 as a novel psychotropic agent. Pharmacol. Biochem. Behav.35(3), 607–615 (1990).
   PubMed Web of Science ®Google Scholar
• Shahid M, Wong E, Walker GB, Baker RA, Jina AS, Zorn S. Asenapine: a novel psychotherapeutic agent with a unique human receptor binding signature. Presented at: ACNP 2005 Annual Meeting. Waikoloa, HI, USA, 11–15 December (2005).
   Google Scholar
• Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J. Psychopharmacol23(1), 65–73 (2009).
   PubMed Web of Science ®Google Scholar
• Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci.68(1), 29–39 (2000).
   PubMed Web of Science ®Google Scholar
• Potkin SG, Cohen M, Baker RA et al. Asenapine, a novel psychopharmacologic agent with efficacy in positive and negative symptoms during acute episodes of schizophrenia: a randomized, placebo and risperidone-controlled trial. Presented at: ACNP 2005 Annual Meeting. HI, USA, 11–15 December (2005).
   Google Scholar
• Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J. Clin. Psychopharmacol.30(2), 106–115 (2010).
   PubMed Web of Science ®Google Scholar
• Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int. J. Clin. Pract.63(12), 1762–1784 (2009).
   PubMed Web of Science ®Google Scholar
• Schoemaker J, Naber D, Vrijland P, Panagides J, Emsley R. Long-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry43(4), 138–146 (2010).
   PubMed Web of Science ®Google Scholar
• Chapel S, Hutmacher MM, Haig G et al. Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. J. Clin. Pharmacol.49(11), 1297–1308 (2009).
   PubMed Web of Science ®Google Scholar
• Preskorn S, Chapel. S, Panagides J. Effect of asenapine versus quetiapine and placebo on QTc interval in patients with schizophrenia. Eur. Neuropsychopharmacol.17(Suppl. 4), S453 (2007).
   Web of Science ®Google Scholar
• Fleming K, Potkin SG, Binneman B, Keller DS, Alphs L, Panagides J. Asenapine improves cognitive function in acute schizophrenia: a placebo- and risperidone-controlled trial. Presented at: American Psychiatric Association 160th Annual Meeting. CA, USA, 19–24 May (2007).
   Google Scholar
• Fleming K, Potkin SG, Binneman B, Keller D, Alph sL, Panagides J. Effects of asenapine on cognitive function in acute schizophrenia: a placebo- and risperidone-controlled trial. Eur. Neuropsychopharmacol.17(Suppl. 4), S466 (2007).
   Web of Science ®Google Scholar
• Potkin SG, Fleming K, Binneman B, Keller DS, Alphs L, Panagides J. Asenapine cognitive function effects in acute schizophrenia: a placebo- and risperidone-controlled trial. Presented at: American Psychiatric Association 160th Annual Meeting. San Diego, CA, USA, 19–24 May (2007).
   Google Scholar
• Alphs L, Panagides J, Lancaster S. Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale. Psychopharmacol. Bull.40(2), 41–53 (2007).
   PubMed Web of Science ®Google Scholar
• Tarazi FI, Moran-Gates T, Massari C, Wong EHF, Henry B, Shahid M. Asenapine displays unique long-term molecular effects on dopamine receptor subtypes. Presented at: ACNP 2005 Annual Meeting. Waikoloa, HI, USA, 11–15 December (2005).
   Google Scholar
• Minassian A, Young JW. Evaluation of the clinical efficacy of asenapine in schizophrenia. Expert Opin. Pharmacother.11(12), 2107–2115 (2010).
   PubMed Web of Science ®Google Scholar
• US FDA. Saphris (Asenapine) sublingual tablets. Briefing book. US FDA, MD, USA (2009).
   Google Scholar
• McIntyre RS. Asenapine: a review of acute and extension phase data in bipolar disorder. CNS Neurosci. Ther. DOI: 10.1111/j.1755-5949.2010.00200.x (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am. J. Psychiatry159(1), 103–108 (2002).
   PubMed Web of Science ®Google Scholar
• Garcia Cabeza I, Sanchez Diaz EI, Sanz Amador M, Gutierrez Rodriguez M, Gonzalez de Chavez M. [Factors related to treatment adherence in schizophrenic patients]. Actas Esp. Psiquiatr.27(4), 211–216 (1999).
   PubMedGoogle Scholar
• McCombs JS, Nichol MB, Stimmel GL, Shi J, Smith RR. Use patterns for antipsychotic medications in medicaid patients with schizophrenia. J. Clin. Psychiatry60(Suppl. 19), 5–11; discussion 12–13 (1999).
   PubMedGoogle Scholar
• Velligan DI, Lam F, Ereshefsky L, Miller AL. Psychopharmacology: perspectives on medication adherence and atypical antipsychotic medications. Psychiatr. Serv.54(5), 665–667 (2003).
   PubMed Web of Science ®Google Scholar
• Thomas P. The stable patient with schizophrenia – from antipsychotic effectiveness to adherence. Eur. Neuropsychopharmacol.17(Suppl. 2), S115–S122 (2007).
   Web of Science ®Google Scholar
• Perkins DO. Clinical trials in schizophrenia with results for the real world. CNS Spectr.11(7 Suppl. 7), 9–13 (2006).
   PubMedGoogle Scholar
• Tamminga CA. Partial dopamine agonists in the treatment of psychosis. J. Neural Transm.109(3), 411–420 (2002).
   PubMed Web of Science ®Google Scholar
• Hudson TJ, Owen RR, Thrush CR et al. A pilot study of barriers to medication adherence in schizophrenia. J. Clin. Psychiatry65(2), 211–216 (2004).
   PubMed Web of Science ®Google Scholar
• Mojtabai R, Lavelle J, Gibson PJ et al. Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996. Psychiatr. Serv.53(3), 337–339 (2002).
   PubMedGoogle Scholar
• Vanelli M, Burstein P, Cramer J. Refill patterns of atypical and conventional antipsychotic medications at a national retail pharmacy chain. Psychiatr. Serv.52(9), 1248–1250 (2001).
   PubMedGoogle Scholar
• Grunebaum MF, Weiden PJ, Olfson M. Medication supervision and adherence of persons with psychotic disorders in residential treatment settings: a pilot study. J. Clin. Psychiatry62(5), 394–399; quiz 400–391 (2001).
   PubMed Web of Science ®Google Scholar
• Cabeza IG, Amador MS, Lopez CA, Gonzalez de Chavez M. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophr. Res.41(2), 349–355 (2000).
   PubMed Web of Science ®Google Scholar
• Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch. Gen. Psychiatry63(6), 679–685 (2006).
   PubMed Web of Science ®Google Scholar
• Casey DE. Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. J. Clin. Psychiatry59(Suppl. 3), 31–37 (1998).
   PubMed Web of Science ®Google Scholar
• Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs18(13), 877–893 (2004).
   PubMed Web of Science ®Google Scholar
• Voruganti LN, Cortese L, Owyeumi L et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr. Res.57(2–3), 201–208 (2002).
   PubMed Web of Science ®Google Scholar
• Voruganti LN, Heslegrave RJ, Awad AG. Quality of life measurement during antipsychotic drug therapy of schizophrenia. J. Psychiatry Neurosci.22(4), 267–274 (1997).
   PubMed Web of Science ®Google Scholar
• Awad AG, Hogan TP, Voruganti LN, Heslegrave RJ. Patients’ subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int. Clin. Psychopharmacol.10(Suppl. 3), 123–132 (1995).
   PubMed Web of Science ®Google Scholar
• Day JC, Bentall RP, Roberts C et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch. Gen. Psychiatry62(7), 717–724 (2005).
   PubMed Web of Science ®Google Scholar
• Sernyak MJ. Implementation of monitoring and management guidelines for second-generation antipsychotics. J. Clin. Psychiatry68(Suppl. 4), 14–18 (2007).
   PubMedGoogle Scholar
• Weiden PJ. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. J. Clin. Psychiatry68(Suppl. 4), 34–39 (2007).
   PubMedGoogle Scholar
• Ganguli R. Behavioral therapy for weight loss in patients with schizophrenia. J. Clin. Psychiatry68(Suppl. 4), 19–25 (2007).
   PubMed Web of Science ®Google Scholar
• Vreeland B. Bridging the gap between mental and physical health: a multidisciplinary approach. J. Clin. Psychiatry68(Suppl. 4), 26–33 (2007).
   PubMed Web of Science ®Google Scholar
• Goff DC. Integrating general health care in private community psychiatry practice. J. Clin. Psychiatry68(Suppl. 4), 49–54 (2007).
   PubMedGoogle Scholar
• Parks JJ. Implementing practice guidelines: lessons from public mental health settings. J. Clin. Psychiatry68(Suppl. 4), 45–48 (2007).
   PubMed Web of Science ®Google Scholar
• Druss BG. Improving medical care for persons with serious mental illness: challenges and solutions. J. Clin. Psychiatry68(Suppl. 4), 40–44 (2007).
   PubMed Web of Science ®Google Scholar
• Pompili M, Girardi P, Ruberto A, Tatarelli R. Toward a new prevention of suicide in schizophrenia. World J. Biol. Psychiatry5(4), 201–210 (2004).
   PubMed Web of Science ®Google Scholar
• Komossa K, Rummel-Kluge C, Hunger H et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. (3), CD006654 (2010).
   Google Scholar
• Komossa K, Rummel-Kluge C, Schmid F et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. (1), CD006625 (2010).
   Google Scholar
• Komossa K, Rummel-Kluge C, Hunger H et al. Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. (1), CD006624 (2010).
   Google Scholar
• Komossa K, Rummel-Kluge C, Hunger H et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. (4), CD006627 (2009).
   Google Scholar
• Komossa K, Rummel-Kluge C, Schmid F et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. (4), CD006569 (2009).
   Google Scholar
• Gilbody SM, Bagnall AM, Duggan L, Tuunainen A. Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database Syst. Rev. (3), CD002306 (2000).
   Google Scholar
• McEvoy JP, Lieberman JA, Perkins DO et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am. J. Psychiatry164(7), 1050–1060 (2007).
   PubMed Web of Science ®Google Scholar